Home

 
 
 

Elevating the Treatment of Cancer

The Summit Is Clear

once you pass through the clouds

We believe that every patient deserves to know what is driving the growth of their cancer and how best to treat it

 
 

Elevating precision medicine to the forefront of every cancer treatment journey

Our vision is a future in which each tumor’s unique genomic test result can be matched with a purpose-built precision medicine.

Together with our drug and diagnostic developer peers, we work to enable a personalized treatment plan for each individual patient with cancer.

Our Focus
 
 
 

Genomic testing illuminates the path

Your tumor has a genomic fingerprint that may help your physician map the best path to overcoming it.

We advocate for every patient to get their tumor genomically tested. Only through testing can we give patients their best chance at improved outcomes.

Learn More About Genomic Testing Patient-Doctor Discussion Guide
 
 
 

Blazing the trail to make genomic test results actionable

We develop drugs to inhibit the specific alterations that have been identified as drivers of cancer ⏤ no matter how rare.

Our lead drug candidate, seribantumab, inhibits tumor growth driven by NRG1 gene fusions. Seribantumab is being studied in CRESTONE, a Phase 2 trial for patients with solid tumors of any origin that test positive for an NRG1 fusion.

Learn More About CRESTONE

Notes from the Trail

SHAWN LELAND | JANUARY 2021

The journey towards our first summit, NRG1 fusions, is well underway. We closed out 2020 with the release of the first preclinical data in support of the Phase 2 CRESTONE study at the EORTC-NCI-AACR conference in October, and a $65M Series B financing in November. We were thrilled to finally be able to publicly share this data showing 50-100% tumor regressions following treatment with seribantumab specifically in NRG1 fusion PDX models, and grateful to see this excitement reflected by our expanded Series B investor syndicate led by venBio and Cormorant Asset Management.

Read the full letter 

NOVEMBER 18, 2020

Elevation Oncology Announces $65M Series B Financing and Promotion of Founder Shawn M. Leland to Chief Executive Officer